阜阳市哪家医院治疗痤疮较好在阜阳治青春痘那家医院好,阜阳市看痤疮去那个,阜阳激光治疗毛囊炎多少钱,阜阳那里有治白斑的医院,阜阳市治疗荨麻疹哪家医院好,阜阳治痤疮都有哪些大医院,阜阳荨麻疹检查费用

WELLINGTON, May 31 (Xinhua) -- New Zealand agricultural produce regulators cleared an Auckland-based firm that exported infant formula to China of food safety concerns, just hours after confirming they had launched an investigation.The clarification came the same day Kiaora New Zealand International, marketers of Heitiki infant formula, apologized for using a Maori name and icon on its product packaging.The Ministry of Agriculture and Forestry (MAF) issued a statement Tuesday to say Kiaora New Zealand had been cleared of food safety and export regulations concerns, but an investigation into the labeling and marketing of Heitiki would continue.The MAF issued a statement earlier Tuesday confirming reports it was investigating the product's safety, but MAF compliance and enforcement director Geoff Allen said in a later statement the investigation had been underway for about 10 days."The investigation was triggered by our internal surveillance. The investigation was primarily on whether there was a food safety issue, and I'm pleased to report that no food safety issues were identified," said Allen.Nothing "untoward" was identified in the origin and export destination of Heitiki-branded products, which were manufactured in New Zealand according to legal requirements, said Allen."The investigation has now turned to the labeling and marketing of the product. This aspect is ongoing, and seeks to identify anything in the labeling or marketing that is inaccurate or misleading.

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

BEIJING, Sept. 6 (Xinhuanet) -- NASA will launch on Thursday twin lunar orbiters built to map the gravity of Earth's moon in unprecedented detail, media reported Tuesday.The twin lunar probes, Graili-A and Graili-B, will blast off from Florida's Cape Canaveral Air Force Station at 8:37 a.m. EDT and at 9:16 a.m. EDT respectively Thursday, according to NASA.The Grail twins will travel three to four months to get to the moon under a slower but more economical plan.Artist concept of GRAIL mission. Grail will fly twin spacecraft in tandem orbits around the moon for several months to measure its gravity field in unprecedented detail.The two spacecrafts will reach the moon around New Year's Day when they will begin to probe the moon's composition from the crust to the core, according to NASA.The data collected by the probes will be used to better understand the moon's evolution and formation, NASA scientists said.Researchers will also use the twin probes to pinpoint the best landing sites for future explorations.The mission, from start to finish, costs 496 million U.S. dollars. The two Grail probes will crash into the moon after its mission.

WASHINGTON, June 14 (Xinhua) -- Eating a low-carbohydrate, high- protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published Tuesday in Cancer Research, a journal of the American Association for Cancer Research.The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered."This shows that something as simple as a change in diet can have an impact on cancer risk," said lead researcher Gerald Krystal, a scientist at the British Columbia Cancer Research Center.Krystal and his colleagues implanted various strains of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical Western diet, contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.As well, mice genetically predisposed to breast cancer were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span ( approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the low-carbohydrate diet developed cancer and more than half these mice reached or exceeded their normal life span.Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.Furthermore, a low-carbohydrate, high-protein diet has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.

SHENZHEN, June 4 (Xinhua) -- Chinese scientists who have fully sequenced the genome of the new E. Coli spreading through Europe said Saturday they found genes in the bacteria that gave it resistance to eight classes of antibiotics.Researchers with the Beijing Genomics Institute, the world's largest DNA sequencing center, have found genes in the newly identified 0104 strain of E. Coli bacteria that made it resistant to major classes of antibiotics including sulfonamide, cephalothin, penicillin and streptomycin.This helped explain why doctors in Europe had difficulties in fighting the bug that has killed 18 people and sickened nearly 2,000, BGI's major research arm in Shenzhen said on its website Saturday.This would help doctors choose right medicines for the treatment, it said.The researchers are developing a diagnostic kit which will be used to detect the bacteria and prevent the epidemic from spreading further.The Chinese researchers obtained DNA samples of the bacteria from collaborating scientists in Germany and fully sequenced its genome in three days this week.They announced on Thursday the E. Coli spreading through Europe was "a new strain of bacteria that is highly infectious and toxic".The 0104 strain of E. Coli was not previously involved in any E. Coli outbreaks. However, it has 93 percent sequence similarity with the EAEC 55989 E. Coli strain which was isolated in the Central African Republic and known to cause seriously diarrhea, BGI said.The source of the outbreak is unknown, but scientists say it is highly likely to have originated in contaminated vegetables or salad in Germany.